DNLI Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Denali Therapeutics Inc (DNLI) does not appear to be a strong buy for a beginner investor with a long-term focus at this time. While there are positive developments such as regaining full control of DNL593 and recent FDA approvals, the company's financial performance remains weak, with significant losses and no revenue growth. Insider selling and neutral hedge fund activity further dampen the sentiment. The technical indicators and options data do not suggest a compelling entry point, and there are no strong trading signals from Intellectia Proprietary Trading Signals. For a long-term investor, it may be better to wait for stronger financial performance or clearer upward momentum before committing funds.
The MACD is negatively expanding, indicating bearish momentum. The RSI is neutral at 44.067, showing no clear signal. Moving averages are converging, suggesting indecision in the market. The stock is trading below the pivot level of 19.92, with key support at 18.117 and resistance at 21.723. Overall, the technical indicators do not suggest a strong buy signal.
Regaining full control of DNL593 from Takeda, which enhances Denali's market position.
FDA accelerated approval of Avlayah for Hunter syndrome, validating the company's platform and transitioning it to a commercial-stage company.
Analysts have raised price targets, with several firms maintaining Buy ratings.
Insiders are selling heavily, with an 844.50% increase in selling activity over the last month.
Weak financial performance, with no revenue growth and significant net losses.
Neutral hedge fund activity, indicating a lack of strong institutional support.
Stock trend analysis suggests a higher probability of short-term declines (-1.45% in the next day, -2.65% in the next week).
In Q4 2025, Denali reported no revenue growth (0% YoY) and a net loss of $128.55 million, which improved by 12.02% YoY. EPS increased to -0.73, up 8.96% YoY. However, the company remains unprofitable, and gross margin is 0%. The financials indicate a company still in the early stages of commercialization with significant risks.
Analysts are generally positive, with multiple firms raising price targets recently. The average price target is significantly higher than the current price, with targets ranging from $31 to $42. Analysts cite the FDA approval of Avlayah and the regained control of DNL593 as key catalysts. However, some caution remains due to the risks associated with the pipeline and prior failures.
